Much of this work has focused on the involvement of the cross-linking enzyme Lysyl Oxidase (LOX) in promoting matrix stiffness, enhancing biomechanical signalling and subsequent aggression [19]; however, recent studies have logically associated TG2 with these events, proposing that this may occur through interactions between cancer cells and fibroblasts associated with the tumour site [20]. The gene discussed is LOX; the disease is neoplasm.